Hansoh Pharmaceutical Group Co. Ltd. published its 2024 Environmental, Social and Governance Report. The report highlights several initiatives and achievements, including eight new innovative drug candidates entering clinical stage, with two in-licensing drug candidates. A self-developed B7-H3 targeting antibody-drug conjugate received Breakthrough Therapy Designation in China, the United States, and Europe. XINYUE (Inebilizumab) was granted priority review for a new indication for the treatment of IgG4-related diseases. Hansoh Pharma also entered into a License-out agreement with MSD, granting MSD exclusive global license for oral GLP-1 receptor agonist HS-10535 under development. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.